Abstract
This study investigated the impact of management of a totally implantable central venous access port device, Port-A-Cath (Smith Medical, St. Paul, MN, USA), on the outcome of 98 cancer patients with candidaemia. Port-A-Cath retention was found to be significantly associated with poorer outcome, independent of other significant adverse factors [breakthrough candidaemia, Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥21, and worse Eastern Cooperative Oncology Group (ECOG) performance score (3-4)]. However, retention of Port-A-Cath devices could be considered in patients who do not have definite catheter-related candidaemia, are not using total parenteral nutrition, do not have poor ECOG performance scores or APACHE II scores, and do not have septic shock.
Original language | English |
---|---|
Pages (from-to) | 281-285 |
Number of pages | 5 |
Journal | Journal of Hospital Infection |
Volume | 82 |
Issue number | 4 |
DOIs | |
Publication status | Published - Dec 2012 |
Externally published | Yes |
Keywords
- Cancer
- Candidaemia
- Port-A-Cath
- Removal
- Retention
- Totally implantable central venous access port
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases